JPRN-jRCT2071230113尚未招募1 期
A Phase 1,randomized,placebo-controlled,double-blind, single ascending dose and multiple ascending dose study of M132101 in healthy subjects.
ishiura Tomoyuki0 个研究点目标入组 48 人开始时间: 2024年2月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 45age old（—）
- 性别
- Male
入选标准
- •Males who are 18 to 44 years of age at the time of informed consent
排除标准
- •(1)Individuals with a history or complications with liver, kidney, or heart disease, etc. considered inappropriate for participation in the clinical study
- •(2)Individuals with abnormal findings (eczema/dermatitis, pigment abnormalities, inflammation due to sunburn, wounds, scars, skin infections, etc.) at the administration site.
- •(3)Individuals who are judged to be unsuitable as subject by the principal (sub) investigator
研究者
相似试验
招募中
不适用
A phase 1, randomized, placebo-controlled, double-blind, single center, multiple-dose, parallel trial evaluating the impact of apraglutide on gastric emptying of liquids in healthy subjectsShort Bowel SyndromeNL-OMON53626VectivBio AG36
未知
1 期
A phase 1, randomized, placebo-controlled, double-blind, multiple oral dose study of DS-8500a in Japanese healthy male subjectsJPRN-jRCT2080223495DAIICHI SANKYO CO., LTD.36
已完成
1 期
A single and multiple dose study of M127101 in healthy subjectsasal polyp accompanies eosinophilic chronic rhinosinusitisJPRN-jRCT2071230019Tomoyuki Nishiura16
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy ParticipantsAlzheimers10012303Alzheimer's DiseaseNL-OMON51440Denali Therapeutics Inc.80
已完成
1 期
Study of ZYN002 (cannabidiol gel) in 40 Healthy VolunteersMental Health - Other mental health disordersNeurological - EpilepsyMusculoskeletal - OsteoarthritisHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersEpilepsyFragile X SyndromeOsteoarthritisACTRN12618000183280Zynerba Pharmaceuticals Pty. Ltd.40